Endo Stock Price, News & Analysis

Endo, Inc. (OTCQX: NDOI) is described in its public communications as a diversified specialty pharmaceutical company that focuses on transforming insights into life‑enhancing therapies. The company appears in the Drug Manufacturers – Specialty & Generic industry within the healthcare sector and is associated with branded pharmaceuticals, sterile injectables, generic pharmaceuticals and, until a recently announced divestiture, an international pharmaceuticals business.

Endo states that its team members collaborate to develop and deliver essential medicines with the goal of helping the people it serves live their best life. Its business is organized into several reportable segments referenced in its financial disclosures: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. These segments reflect the company’s focus on both specialty brands and generic or hospital‑focused products.

Business Segments and Therapeutic Focus

In the Branded Pharmaceuticals segment, Endo highlights products such as XIAFLEX, SUPPRELIN LA and other specialty and established brands. XIAFLEX (collagenase clostridium histolyticum) is described as the only FDA‑approved nonsurgical treatment for Peyronie’s disease, and Endo has also supported studies of collagenase clostridium histolyticum in conditions such as plantar fibromatosis and plantar fasciitis. The company has created educational tools such as a Spatial Computing Injection Simulator to help urology specialists refine injection technique for XIAFLEX in Peyronie’s disease.

The Sterile Injectables segment includes products such as ADRENALIN (epinephrine) and VASOSTRICT, along with other sterile injectable therapies. Endo has emphasized its Endo Injectable Solutions TruDelivery platform, which features ready‑to‑use premixed intravenous bags such as ADRENALIN premixed IV bags. According to company communications, these ready‑to‑use products are intended to simplify hospital pharmacy workflows by eliminating the need for on‑site compounding or preparation before administration.

The Generic Pharmaceuticals segment comprises a portfolio of generic versions of branded products, distributed primarily in the United States. Endo’s disclosures note that this segment includes products such as dexlansoprazole delayed‑release capsules and lidocaine patch 5%, among others, with revenues influenced by competitive dynamics in the generic market. The International Pharmaceuticals segment, operated primarily through Paladin Pharma Inc., has been the subject of a completed divestiture to Knight Therapeutics Inc., as announced by Endo.

Clinical Development and Research Activities

Endo describes an active clinical development strategy, particularly around collagenase clostridium histolyticum. The company has supported Phase 1 and Phase 2 studies of collagenase clostridium histolyticum in plantar fasciitis (PFA) and plantar fibromatosis (PFI), and it reports that it is enrolling patients in a pivotal Phase 3 program for PFI. A post hoc analysis of a Phase 2 PFI study identified a subgroup of patients who appeared to respond well to treatment, with reported improvements in pain, nodule hardness and overall condition compared to placebo in that subgroup. Endo has also supported retrospective analyses of patient experiences with PFI, highlighting the burden of pain and interest in nonsurgical options.

In plantar fasciitis, Endo references a Phase 1 proof‑of‑concept study assessing the safety, tolerability and effectiveness of a single dose of collagenase clostridium histolyticum. The company notes that the safety profile aligned with known adverse events and that improvements were observed across effectiveness measures compared to placebo, which supported further investigation in a Phase 2 trial.

Hospital‑Focused Sterile Injectables

Endo’s sterile injectables communications emphasize ADRENALIN premixed IV bags as FDA‑approved, manufacturer‑prepared epinephrine premixed intravenous bags. The company highlights features such as no compounding or preparation requirement, single‑port IV tubing and room‑temperature shelf life, and positions these attributes as supporting hospital operations by reducing preparation steps, potential waste and the chance for preparation error. ADRENALIN is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock, and Endo provides extensive safety and prescribing information in its product communications.

Educational and Technology‑Enabled Initiatives

Endo has described the use of spatial computing or mixed reality technologies to support healthcare provider education. The Spatial Computing Injection Simulator for Peyronie’s disease blends a physical model with digital content delivered via an Apple Vision Pro app, allowing urology specialists to practice reconstitution, injection angles and post‑injection steps for XIAFLEX administration. The company notes that this is its second spatial computing experience, following an earlier tool for hand specialists treating Dupuytren’s contracture.

Corporate Transactions and Strategic Direction

Endo has announced several significant corporate transactions. It entered into a definitive agreement with Mallinckrodt plc to combine the two companies in a stock and cash transaction. Shareholders of both Endo and Mallinckrodt have approved the combination, and the Irish High Court has issued a ruling enabling the transaction to proceed, with completion expected following remaining closing steps. Under the agreement, Mallinckrodt will continue as the holding company for the combined business, and Endo will become a wholly owned subsidiary of Mallinckrodt. The combined company is expected to have its global headquarters in Dublin, Ireland, where Mallinckrodt is based.

Following the combination, Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo’s sterile injectables business and later separate that combined generics and sterile injectables business into an independent entity, intended to be called Par Health, subject to board and other approvals. Endo has also completed the divestiture of its International Pharmaceuticals business, primarily operated through Paladin Pharma Inc., to Knight Therapeutics Inc., for cash consideration that includes amounts paid at closing, permitted holdbacks and potential milestone‑based payments.

Financial Reporting and Segment Disclosure

Endo reports financial results by segment, including Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. In its first‑quarter 2025 financial update, the company discussed segment revenues, noting growth in XIAFLEX within Branded Pharmaceuticals and competitive pressures in Sterile Injectables and Generic Pharmaceuticals. The company also reaffirmed its full‑year 2025 revenue and adjusted EBITDA guidance in that update and referenced its ongoing transformation, including the proposed combination with Mallinckrodt and the International Pharmaceuticals divestiture.

Status of NDOI Stock

Endo, Inc. common stock trades on the OTCQX market under the ticker symbol NDOI. Company communications describe NDOI in connection with financial results, transaction announcements and product launches. As of the information provided, Endo remains an operating pharmaceutical company that has agreed to a merger under which it will become a wholly owned subsidiary of Mallinckrodt, with Endo shareholders receiving cash and a pro forma ownership stake in the combined company.

FAQs about Endo, Inc. (NDOI)

• What does Endo, Inc. do?
  Endo, Inc. describes itself as a diversified specialty pharmaceutical company that develops and delivers life‑enhancing therapies. It operates through Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and, prior to a completed sale, International Pharmaceuticals segments.
• What are Endo’s main business segments?
  Endo reports four segments in its financial disclosures: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. These segments reflect its focus on specialty brands, hospital‑focused sterile injectables, U.S. generics and, until divestiture, international operations.
• Which products does Endo highlight in its communications?
  Endo highlights branded products such as XIAFLEX and SUPPRELIN LA, sterile injectables including ADRENALIN and VASOSTRICT, and generic products such as lidocaine patch 5% and dexlansoprazole delayed‑release capsules, among others referenced in its segment tables.
• What therapeutic areas is Endo involved in?
  Endo’s communications reference conditions such as Peyronie’s disease, Dupuytren’s contracture, plantar fibromatosis, plantar fasciitis and hypotension associated with septic shock, reflecting its activity in urology, musculoskeletal disorders and critical care settings.
• What is the relationship between Endo and Mallinckrodt?
  Endo and Mallinckrodt have entered into a definitive agreement to combine in a stock and cash transaction. Shareholders of both companies have approved the combination, and the Irish High Court has issued a ruling enabling the transaction, with completion expected after remaining closing steps. After closing, Endo will become a wholly owned subsidiary of Mallinckrodt.
• What is Par Health in relation to Endo?
  Mallinckrodt and Endo have announced plans that, after their merger closes, their combined generic pharmaceuticals businesses and Endo’s sterile injectables business are intended to be separated into an independent entity called Par Health, subject to board and other approvals.
• Has Endo divested any businesses recently?
  Endo has announced the completion of the divestiture of its International Pharmaceuticals business, primarily operated through Paladin Pharma Inc., to Knight Therapeutics Inc., for cash consideration that includes upfront, holdback and potential milestone‑based payments.
• What stock market is NDOI traded on?
  Endo, Inc. common stock is referenced as trading on the OTCQX market under the ticker symbol NDOI.
• How does Endo use technology in medical education?
  Endo has developed spatial computing experiences, including a Spatial Computing Injection Simulator for Peyronie’s disease delivered via an Apple Vision Pro app, to help healthcare providers practice injection techniques for XIAFLEX.
• Does Endo conduct clinical research?
  Yes. Endo supports clinical and proof‑of‑concept studies, including Phase 1, Phase 2 and Phase 3 programs involving collagenase clostridium histolyticum for conditions such as plantar fibromatosis and plantar fasciitis, as well as retrospective analyses of patient experiences.